Yahoo · Nov 9, 2026
Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report 2026: Capitalize on 13.5% CAGR to $2.4 Billion by 2032 Featuring Covance, Crown Bioscience, Personalis and Promega
Outsourcing to specialized global CROs, supported by AI and NGS, reduces costs, accelerates discovery, lowers failure risk and sharpens focus on commercializationDublin, Nov. 09, 2026 (GLOBE NEWSWIRE) -- "Cancer Immunotherapy Drug Discovery Outsourcing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global cancer immunotherapy drug discovery outsourcing market, valued at US$985.6 million in 2025, is projected to reach US$2.4 billion by 2032. The marke

